ASMB - Assembly Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Assembly Biosciences, Inc.

11711 North Meridian Street
Suite 310
Carmel, IN 46032
United States
317-210-9311
http://www.assemblybio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees103

Key Executives

NameTitlePayExercisedYear Born
Mr. Derek A. SmallCo-Founder, Pres, CEO, Principal Financial Officer & Director890.97kN/A1976
Dr. Uri A. LopatinCo-Founder and Clinical & Scientific Advisor608.55kN/A1972
Dr. Richard J. ColonnoExec. VP & Chief Scientific Officer of Virology Operations646.38kN/A1950
Ms. Jacqueline Sybil PapkoffSr. VP & Chief Scientific Officer of Microbiome477.17kN/A1956
Mr. David J. Barrett CPAConsultant980.26k10.26M1976
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in two Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in investigational new drug-enabling studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, and immuno-oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Corporate Governance

Assembly Biosciences, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 2; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.